Scarica l'app Stockscreener
14.14
1.53%
-0.22
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Amarin Corp Adr Borsa (AMRN) Ultime notizie
China Universal Asset Management Co. Ltd. Sells 76,302 Shares of Amarin Corporation PLC $AMRN - Defense World
Companies Like Amarin (NASDAQ:AMRN) Are In A Position To Invest In Growth - Sahm
Tops & Flops Stocks - sharewise.com
RECORDATI FIRST NINE MONTHS 2025 RESULTS: REVENUE +12.2%, EBITDA(1) +11.8%, ADJUSTED NET INCOME(2) +10.7%; ISTURISA PEAK SALES ESTIMATE DOUBLED TO GREATER THAN € 1.2 BILLION - GlobeNewswire Inc.
Amarin (AMRN) Unprofitable as Losses Worsen, Profit Growth Forecasts Test Bullish Turnaround Hopes - Sahm
Amarin Announces Plan to Initiate a Ratio Change Under Its American Depository Receipt (ADR) Program - ADVFN
Cash from operating activities of Amarin Corporation Plc Sponsored ADR – SWB:EH3 - TradingView
Amarin Corporation plc (NASDAQ:AMRN) Stock Catapults 25% Though Its Price And Business Still Lag The Industry - Sahm
Amarin Corporation plc Announces $17.8 Million Registered Direct Offering of American Depositary Shares - ADVFN
Amarin stock rises after ESC Congress data on VASCEPA mechanism - Investing.com
Earnings call transcript: Amarin Q2 2025 sees revenue beat, stock stable - Investing.com
Amarin's Q2 Earnings & Revenues Trump Estimates, Stock Rises - Barchart.com
Amarin Gears Up To Report Q2 Earnings: Here's What To Expect - Barchart.com
VKTX Stock Down On Wider-Than-Expected Loss In Q2, Nil Sales - Barchart.com
Zacks.com featured highlights include Mama's Creations, Bassett Furniture Industries and Amarin - Barchart.com
3 Strong Buy Breakout Stocks for Explosive Returns - The Globe and Mail
KRYS Begins Dosing With Gene Therapy In Rare Eye Disease, Stock Up - Barchart.com
RYTM Stock Rises On Upbeat Acquired Hypothalamic Obesity Study Data - Barchart.com
PROK Surges More Than 500% On Upbeat Data From Kidney Cell Therapy Study - Barchart.com
Amarin Soars 27% on Vazkepa Licensing Deal With Recordati in the EU - Yahoo Finance
Amarin stock jumps after $25 million licensing deal with Recordati - Investing.com
Is Amarin (AMRN) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
SNY's Rilzabrutinib Wins 4th Orphan Drug Tag for Sickle Cell Disease - Finviz
Is GSK PLC Sponsored ADR (GSK) Outperforming Other Medical Stocks This Year? - Yahoo Finance
TEVA Begins IND-Enabling Studies on Inflammatory Disease Candidate - Finviz
SpringWorks Gets CHMP Nod For Mirdametinib In Rare Disease - Barchart.com
Amarin earnings beat by $0.04, revenue topped estimates - Investing.com
Amarin Corp PLC Share Price ADR Each Rep 20 Ord Spon - Hargreaves Lansdown
Amarin announces ADS ratio change to meet Nasdaq requirements - Investing.com
Amarin adds investment expert Michael Torok to Board By Investing.com - Investing.com
Amarin announces board member departure ahead of annual meeting - Investing.com
European Equities Traded in the US as American Depositary Receipts Higher in Monday Trading - TradingView
Amarin urged to review strategy by major shareholders - Investing.com
The Market Doesn't Like What It Sees From Amarin Corporation plc's (NASDAQ:AMRN) Revenues Yet As Shares Tumble 26% - Sahm
Amarin Corp PLC (AMRN) Q4 2024 Earnings Call Highlights: Navigating Challenges and Expanding ... - Yahoo Finance
Amarin Announces 1-for-20 Reverse Stock Split - TipRanks
Amarin stock plunges to 52-week low of $0.46 amid challenges - Investing.com
Amarin granted extension to meet Nasdaq listing standards - Investing.com
Invesco Nasdaq Biotechnology ETF Holdings - Quiver Quantitative
Amarin to present new cardiovascular research at ESC Congress - Investing.com
China approves VASCEPA to reduce cardiovascular risk - Investing.com
Why Core & Main Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session - Investing.com UK
Amarin's VAZKEPA gains reimbursement approval in Greece - Investing.com
Amarin secures new patent for heart drug VAZKEPA in Europe - Investing.com
Free float of Amarin Corporation Plc Sponsored ADR – NASDAQ:AMRN - TradingView
symbol__ Stock Quote Price and Forecast - CNN
Sarissa Capital Calls for Amarin Special Meeting to Vote on Its Nominees - 24/7 Wall St.
股神出手｜畢菲特首度買進台積電ADR 涉逾41.2億美元 4家避險基金均增持台積電 - Yahoo 財經
Amarin CorpADR (AMRN) News, Articles, Events & Latest Updates - Stocktwits
Validea Kenneth Fisher Strategy Daily Upgrade Report9/24/2022 - Nasdaq
AMRN Forecast — Price Target — Prediction for 2026 - TradingView
Amarin (AMRN) Q2 Earnings & Sales Hurt by Vazkepa Generics - Nasdaq
HLS Announces that Vascepa® is now reimbursed by Ontario's Provincial Drug Plan - The Globe and Mail
The Daily Biotech Pulse: Amarin Vascepa Data, Galapagos Osteoarthritis Drug Update, 4 IPOs - Yahoo Finance
Amarin Stock Melts Down After Losing Patent Battle For Heart Drug - Investor's Business Daily
Amarin stock heads toward highest prices in more than a decade after new Vascepa FDA approval - MarketWatch
This Biotech Stock Just Got A Highly Anticipated FDA Approval - Investor's Business Daily
Heart Drugs Are Having a Moment - Bloomberg.com
62 Stocks Doubled In 2018 - Investing.com
Fish-Oil Heart Medicine Is Rarest of Drug Breakthroughs - Bloomberg
10 Cheap Stocks to Buy With Only $12 - Nasdaq
AMRN Stock Price and Chart — NASDAQ:AMRN - TradingView
Amarin Corporation plc (AMRN) stock price, news, quote and history - Yahoo Finance UK
PRTA Stock Price | Prothena Corp. PLC Stock Quote (U.S.: Nasdaq) - MarketWatch
The Healthcare Gurus at Baker Bros. Advisors Were Buying These Stocks in Q3 - Insider Monkey
AMRNAmarin Corp ADR Stock Price and Quote - Finviz
ADR港股比例指數對港股走勢會產生什麼影響？ - Yahoo 財經
What Hedge Funds Think About Terraping 3 Acquisition Corp (TRTL)? - Insider Monkey
The Best- And Worst-Performing Biotech Stocks Of 2013 - Forbes
Amarin Corporation plc (ADR) (AMRN) News: Struggle, New Announcement & AstraZeneca Plc (AZN)’s Dominance - Insider Monkey
Trending News: Wal-Mart Stores, Inc. (WMT), Amarin Corporation plc (ADR) (AMRN), Verizon Communications Inc. (VZ) - Insider Monkey
AMRN Stock Price | Amarin Corp. PLC ADR Stock Quote (U.S.: Nasdaq) - MarketWatch
1.77%
2.24%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):